01—Abstract
Summary
Summary of the 8-K filed January 21, 2025. Cited figures are marked; the original filing is the authoritative source.
3M reported fourth-quarter and full-year 2024 results on January 21, 2025, with mixed headline performance but a clear improvement in underlying profitability.
Q4 GAAP sales were $6.0 billiona (up 0.1% YoY) and adjusted sales were $5.8 billion (up 2.2%, with 2.1% adjusted organic growth). Q4 GAAP EPS from continuing operations rose 17% to $1.33, while adjusted EPS of $1.68 declined 2%. For the full year, GAAP sales were $24.6 billion (down 0.1%), adjusted sales were $23.6 billion (up 1.3%, with 1.2% adjusted organic growth), and adjusted EPS of $7.30 rose 21%.
Full-year GAAP EPS from continuing operations was $7.26b, boosted by a $2.83 per-share gain from the increased value of its Solventum stake, which offset litigation costs and a pension risk transfer charge. Cash generation was heavily affected by litigation payments. Operating cash flow was $1.8 billion for the year, including $3.8 billion of after-tax payments for significant litigation, primarily Public Water Systems and Combat Arms Earplugs settlements.
Adjusted free cash flow was $4.9 billionc, and 3M returned $3.8 billion to shareholders through dividends and buybacks. Net debt fell sharply to $5.3 billion from $10.2 billion a year earlier, though this partly reflects the Solventum separation.
For 2025, 3M guided to adjusted sales growth of 0.5% to 1.5% (adjusted organic growth of 2% to 3%), adjusted EPS of $7.60 to $7.90d, and adjusted operating cash flow of $5.2 to $5.3 billion, implying roughly 100% adjusted free cash flow conversion. The guidance excludes the PFAS manufacturing exit, which management plans to complete by the end of 2025, and it does not forecast GAAP figures or special items such as litigation costs.
02—Key points
Key Highlights
- Q4 2024 GAAP EPS from continuing operations rose 17% to $1.33, while adjusted EPS fell 2% to $1.68 year over year.
- Full-year 2024 adjusted organic sales grew 1.2%, a return to positive organic growth after the GAAP figure was slightly negative (-0.2%).
- Full-year 2024 adjusted EPS of $7.30 rose 21%, while GAAP EPS of $7.26 was inflated by a $2.83 per-share gain on the Solventum stake.
- Operating cash flow of $1.8 billion was depressed by $3.8 billion of after-tax litigation payments; adjusted free cash flow was $4.9 billion.
- Net debt dropped to $5.3 billion from $10.2 billion, and 3M returned $3.8 billion to shareholders in 2024.
- 2025 guidance calls for adjusted EPS of $7.60 to $7.90 and adjusted organic sales growth of 2% to 3%, with adjusted total sales growth of 0.5% to 1.5%.
- 2025 adjusted operating cash flow of $5.2 to $5.3 billion implies roughly 100% adjusted free cash flow conversion.
03—Questions
Frequently Asked Questions
Why do GAAP and adjusted EPS diverge so much for 2024?
GAAP EPS of $7.26 includes a $2.83 per-share gain from the increase in value of 3M's retained Solventum stake, which boosts reported earnings. It is offset by a $1.32 per-share cost for significant litigation and a $1.11 per-share pension risk transfer charge. Adjusted EPS of $7.30 strips out these items, so investors typically focus on it for underlying performance.
How much did litigation affect 3M's cash flow in 2024?
Litigation was the dominant cash item. 3M paid about $3.8 billion after tax for significant litigation, primarily Public Water Systems and Combat Arms Earplugs settlements. This reduced reported operating cash flow to $1.8 billion from $6.7 billion in 2023. Adjusted free cash flow, which excludes these payments, was $4.9 billion.
What is driving the 2025 guidance, and what is excluded?
Guidance assumes adjusted organic sales growth of 2% to 3%, with total adjusted sales growth of 0.5% to 1.5% after roughly 2% of translation headwind. The outlook excludes the impact of manufactured PFAS products, which 3M plans to exit by the end of 2025. Because 3M cannot reliably forecast items such as litigation costs and Solventum stake value changes, it does not provide GAAP guidance.
Is 3M's balance sheet stronger after the Solventum spin-off?
Yes, on a net debt basis. Net debt fell to $5.3 billion at year-end 2024 from $10.2 billion a year earlier, as total debt decreased and cash plus marketable securities rose to $7.7 billion. Total equity, however, declined to $3.9 billion from $4.9 billion, and total liabilities remain large at $36.0 billion, largely due to litigation-related obligations.
04—Continue